-

SQZ Biotech to Present at Jefferies Virtual Health Care Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participating in the Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. Armon Sharei, PhD, chief executive officer, will present a corporate overview on June 2 at 3:00 pm EDT with a virtual webcast and host one on one meetings.

More information about and access to the webcast for the presentation are available on the Investors & Media section of the company website. The webcast will be available for 30 days following the presentation.

About SQZ Biotechnologies

SQZ Biotechnologies is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using its proprietary technology, SQZ Biotechnologies offers the unique ability to deliver multiple materials into many patient cell types to engineer what we believe can be an unprecedented range of potential therapeutics for a variety of diseases. SQZ Biotechnologies has the potential to create well-tolerated cell therapies that can provide therapeutic benefit for patients and to improve the patient experience over existing cell therapy approaches. With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, our goal is to use the SQZ approach to establish a new paradigm for cell therapies. Our first therapeutic applications aim to leverage the potential to generate target-specific immune responses, both in activation for the treatment of solid tumors and immune tolerance for the treatment of unwanted immune reactions and autoimmune diseases. For more information, please visit www.sqzbiotech.com.

Contacts

SQZ Biotechnologies IR Contact:
investors@sqzbiotech.com

SQZ Biotechnologies Media Contact:
John Lacey
Corporate Communications
john.lacey@sqzbiotech.com
781-392-5514

SQZ Biotechnologies Company

NYSE:SQZ

Release Versions

Contacts

SQZ Biotechnologies IR Contact:
investors@sqzbiotech.com

SQZ Biotechnologies Media Contact:
John Lacey
Corporate Communications
john.lacey@sqzbiotech.com
781-392-5514

More News From SQZ Biotechnologies Company

SQZ Biotechnologies Announces $2 Million Grant From the National Institutes of Health to Develop a Novel, Scalable Cell Replacement Therapy for Parkinson’s Disease

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it has been awarded a $2 million SBIR Phase II grant from the National Institute of General Medical Sciences, a division of the National Institutes of Health. Awarded through a competitive process, the two-year grant will support the development of cell engineering methods that are designed to reprogram a patient’s own...

SQZ Biotechnologies Reports Full Year 2021 Financial Results and Recent Portfolio Updates

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today reported full year 2021 financial results and recent portfolio updates. “We have much to be proud of as 2021 was a year of significant milestones for SQZ—a major highlight was that our lead APC candidate demonstrated monotherapy clinical benefit in an advanced patient as well as favorable safety data and tolerability across all patie...

SQZ Biotechnologies to Present New Enhanced APC Platform Preclinical Findings and ENVOY-001 Phase 1/2 Clinical Trial in Progress Poster at the American Association for Cancer Research 2022 Annual Meeting

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), focused on unlocking the full potential of cell therapies for multiple therapeutic areas, today announced that it will present new preclinical findings on the company’s enhanced antigen presenting cell (eAPC) platform at the American Association for Cancer Research (AACR) Annual Meeting on April 8-13, 2022 in New Orleans, Louisiana. The new eAPC work demonstrates the company’s Cell Squeeze® platform’s ability to deliver...
Back to Newsroom